
https://www.science.org/content/blog-post/failure-modern-medicine
# The Failure of Modern Medicine? (June 2011)

## 1. SUMMARY  
The piece is a short Forbes blog post by Matthew Herper that was written as a rebuttal to a July‑2011 Atlantic article titled “The Triumph of New‑Age Medicine.” The Atlantic essay argued that modern, allopathic medicine has made little progress against chronic illnesses such as heart disease and cancer, and that this perceived failure is driving patients toward “alternative” modalities (acupuncture, herbal remedies, etc.) that emphasize prevention.  

Herper counters the claim point‑by‑point. He cites CDC mortality data to show that death rates from both heart disease and cancer have been on a long‑term decline, arguing that the “slow, grinding trench warfare” of medical progress is still winning. He also disputes the notion that conventional medicine ignores prevention, noting that preventive guidelines (e.g., cholesterol screening, smoking cessation, vaccination) are central to modern practice. Finally, he suggests that the popularity of alternative therapies is less about their efficacy and more about a “secret ingredient” that has been stripped from mainstream care—implying a loss of the therapeutic relationship, time, and holistic attention that patients value.

## 2. HISTORY  

**Mortality trends (2011‑2025)**  
- **Cardiovascular disease:** Age‑adjusted death rates in the United States fell from ~210 per 100 000 in 2010 to ~150 per 100 000 by 2022, driven by widespread statin use, better hypertension control, and advances in interventional cardiology (e.g., drug‑eluting stents, transcatheter aortic valve replacement). The decline slowed after 2018 as obesity and diabetes rates rose, but the overall trend remains downward.  
- **Cancer:** After a modest plateau in overall cancer mortality around 2011‑2014, the U.S. saw a renewed decline of roughly 1–2 % per year from 2015 onward, largely attributable to immunotherapies (PD‑1/PD‑L1 checkpoint inhibitors) and targeted agents (e.g., BRAF, EGFR inhibitors). Lung‑cancer mortality dropped sharply after 2015 because of low‑dose CT screening and targeted therapies for EGFR/ALK‑positive tumors.  

**Therapeutic advances**  
- **Immuno‑oncology:** First FDA approvals of checkpoint inhibitors (ipilimumab 2011, pembrolizumab 2014) opened a new era; by 2023, over 20 such agents were approved for multiple tumor types, delivering durable responses in a subset of patients.  
- **Gene‑editing & RNA therapeutics:** The first CRISPR‑based in‑human trial (CTX001 for sickle cell disease) began in 2020, and the first FDA‑approved RNA‑interference drug (patisiran, 2018) demonstrated that nucleic‑acid medicines can move from concept to clinic.  
- **Cardiovascular devices:** Transcatheter aortic valve replacement (TAVR) expanded from high‑risk to low‑risk patients, now accounting for >60 % of aortic valve replacements in the U.S.  

**Alternative‑medicine landscape**  
- **Acupuncture:** Utilization remained stable (~4 % of U.S. adults reported use in 2012; ~4.5 % in 2022). Insurance coverage for acupuncture grew modestly, especially for chronic pain, but high‑quality RCT evidence remains limited to specific indications (e.g., postoperative nausea, migraine).  
- **Integrative medicine:** The National Center for Complementary and Integrative Health (NCCIH) continued to fund research, producing modest evidence for mind‑body interventions (e.g., mindfulness, yoga) in stress reduction. Academic medical centers increasingly offered “integrative” clinics, but these are adjuncts rather than replacements for standard care.  

**Policy and public perception**  
- The Affordable Care Act (2010) mandated coverage of preventive services without cost‑sharing, reinforcing the claim that mainstream medicine does prioritize prevention.  
- The 2020 “Truth in Advertising” rule by the FTC tightened claims made by supplement manufacturers, curbing some of the most egregious misinformation that had fueled alternative‑medicine hype.  

Overall, the data since 2011 show continued, measurable progress against the chronic diseases highlighted in the Atlantic article, while the popularity of alternative therapies has neither exploded nor vanished.

## 3. PREDICTIONS  

| Prediction (as implied or stated in the 2011 commentary) | What actually happened |
|---|---|
| **Modern medicine is not making strides against heart disease and cancer.** | False. Age‑adjusted mortality for both conditions continued to decline, with notable breakthroughs in oncology (immunotherapy, targeted therapy) and cardiology (statins, TAVR, PCSK9 inhibitors). |
| **Alternative medicine focuses on prevention, whereas mainstream medicine does not.** | Partially false. Mainstream medicine has long emphasized primary and secondary prevention (vaccines, screenings, lifestyle counseling). Alternative modalities often market “prevention” but lack robust evidence for most claims. |
| **The “secret ingredient” removed from modern practice fuels the appeal of alternatives.** | The “secret ingredient” (interpreted as time‑intensive patient interaction) remains a genuine gap; many health systems have responded by integrating behavioral health, patient‑navigator programs, and “integrative” clinics. However, this has not translated into a wholesale shift toward unproven alternative therapies. |
| **Alternative therapies will continue to gain mainstream acceptance and market share.** | Mixed. Use of acupuncture and mind‑body practices grew modestly, especially for chronic pain and mental‑health support, but they remain a small fraction of overall healthcare spending (<2 % of U.S. health‑care expenditures in 2023). No major alternative therapy has become a standard of care for chronic disease management. |

## 4. INTEREST  
**Rating: 7/10**  
The article is a concise, timely critique of a high‑profile media piece, and it touches on enduring debates about the efficacy of conventional versus alternative medicine—issues that remain relevant as both fields evolve. Its relevance is bolstered by the clear, data‑driven counter‑argument, though the piece itself is brief and does not introduce novel research, limiting its long‑term scholarly impact.


----
_model_params = {'model': 'openai/gpt-oss-120b:free', 'input': '20110615-failure-modern-medicine.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_